Type 2 Diabetes Medications: Mechanisms, Classes, and Selection Guide

Pharmacologic Toolkit for T2D: Matching Drug to Patient

Nine major drug classes target distinct pathophysiologic defects. Selection follows ADA/EASD 2024 algorithm: prioritize cardio-renal protection, hypoglycemia risk, weight effect, cost, and patient preference.

Mechanism-Based Classification

ClassKey AgentsPrimary MechanismWeightHypo RiskCardio-Renal Benefit
BiguanideMetformin↓ Hepatic gluconeogenesis; ↑ insulin sensitivity (AMPK)Neutral/↓NoneCV neutral (UKPDS legacy)
SulfonylureasGlipizide, glimepiride, glyburide↑ Insulin secretion (KATP closure)↑ 2–4 kgModerateNeutral
MeglitinidesRepaglinide, nateglinideRapid, short-acting insulin secretion↑Low (short action)Neutral
TZDsPioglitazone, rosiglitazonePPAR-γ agonist → ↑ insulin sensitivity (adipose)↑ 3–5 kgLowPioglitazone: ↓ stroke, ↑ HF
DPP-4iSitagliptin, linagliptin, saxagliptin, alogliptin↑ GLP-1/GIP (inhibit degradation)NeutralNoneNeutral (saxagliptin/alogliptin: ↑ HF hosp)
SGLT2iEmpagliflozin, dapagliflozin, canagliflozin, ertugliflozin↓ Renal glucose reabsorption → glycosuria↓ 2–3 kgNone (mono)Strong: ↓ MACE, HF hosp, CKD progression
GLP-1 RASemaglutide, liraglutide, dulaglutide, tirzepatide (GIP/GLP-1)↑ Insulin, ↓ glucagon, ↓ gastric emptying, ↑ satiety↓↓ 5–15%None (mono)Strong: ↓ MACE, CKD (some)
Alpha-glucosidase inhibitorsAcarbose, miglitolDelay carb absorption (gut)Neutral/↓NoneNeutral
Bile acid sequestrantColesevelam↑ GLP-1, ↓ hepatic glucoseNeutralNoneLDL ↓; CV neutral
Dopamine-2 agonistBromocriptine QRCentral circadian resetNeutralNoneNeutral

Selection Algorithm (Simplified)

  1. ASCVD / high CV risk / CKD / HF: Start SGLT2i or GLP-1 RA with proven benefit (even if HbA1c near target).
  2. Need weight loss: GLP-1 RA > SGLT2i > metformin.
  3. Hypoglycemia avoidance critical: Avoid SU/meglitinide/insulin; prefer SGLT2i, GLP-1 RA, DPP-4i, metformin, TZD.
  4. Cost/access barriers: Metformin → SU (glipizide) → basal insulin (NPH/glargine biosimilar).
  5. Renal impairment: Dose-adjust per eGFR. Linagliptin (no adjust), SGLT2i approved down to eGFR 20 (dapagliflozin/empagliflozin).
  6. Injection aversion: Oral agents first; oral semaglutide (Rybelsus) now available.

Combination Principles

  • Complementary mechanisms (e.g., metformin + SGLT2i + GLP-1 RA = "triple therapy" with additive efficacy, low hypo, weight loss, organ protection).
  • Avoid SU + insulin (high hypo) unless necessary.
  • De-intensify if HbA1c <6.5% with hypoglycemia risk (elderly, CKD).

Emerging: Tirzepatide (GIP/GLP-1 Dual Agonist)

SURPASS/SURMOUNT trials: HbA1c ↓ 2.0–2.3%, weight ↓ 15–22%. Approved T2D (2022) & obesity (2023). Redefines efficacy ceiling.

Prescribing pearl: Start low, go slow, counsel on GI side effects (GLP-1 RA), genital mycotic infections (SGLT2i), euglycemic DKA risk (SGLT2i — educate on sick days, low-carb, alcohol).

Diabetes - Related Articles